Literature DB >> 29886396

Reproducible evaluation of tumor-infiltrating lymphocytes (TILs) using the recommendations of International TILs Working Group 2014.

Yumi A Kojima1, Xiaohong Wang2, Hongxia Sun1, Frances Compton2, Michael Covinsky2, Songlin Zhang3.   

Abstract

Tumor infiltrating lymphocytes (TILs) in breast cancer play an important role in predicting the outcome of breast cancer. The goal of our current study is to investigate the consistency and reproducibility of the recommendations published by the International TILs Working Group 2014 among pathology trainees and pathologists. Hematoxylin &amp; Eosin (H&amp;E) slides from 129 breast cancer cases (one slide each) from 2009 to 2014 were evaluated. Each case was blindly and independently reviewed by two observers following the International TILs Working Group 2014 recommendations. Three pathology trainees (PGY2, PGY3 and PGY4) and three pathologists (2 general pathologists and 1 breast pathologist) were involved in this study. Of the 129 cases, 10 (10/129, 7.8%) cases had TILs >50%, 90 (90/129, 69.8%) cases had <10% of TILs, and 29 (29/129, 22.4%) cases had TILs ranging from 10 to 50%. Our results showed that in 104 cases (104/129, 80.6%) the TILs percentage was identical between the 2 observers. In 18 cases (18/129, 14%), the difference between the two observers was by 10% and in 7 cases (7/129, 5.4%) there was a difference of 20% or more. The inter-observer kappa value was 0.776 between two observers, and the kappa score improved to 0.86 if using the 3 categoric groups (<10%, 10-50%, and >50%). Our study showed that the recommendations and instructions for TILs evaluation by the International TILs Working Group 2014 were sufficiently detailed to be applied for TILs evaluation in breast cancer.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Inter-observer agreement; International TILs Working Group; Kappa value; Pathology trainees; Tumor infiltrating lymphocytes

Mesh:

Year:  2018        PMID: 29886396     DOI: 10.1016/j.anndiagpath.2018.05.007

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  5 in total

1.  Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial.

Authors:  Xiaorong Zhong; Ping He; Jie Chen; Xi Yan; Bin Wei; Zhang Zhang; Hong Bu; Jing Li; Tinglun Tian; Qing Lv; Xiaodong Wang; Hongjiang Li; Jing Wang; Juan Huang; Jiaojiao Suo; Xiaoxiao Liu; Hong Zheng; Ting Luo
Journal:  Gland Surg       Date:  2022-01

Review 2.  [Standardized determination of tumor-infiltrating lymphocytes in breast cancer : A prognostic marker for histological diagnosis].

Authors:  C Denkert; S Loibl; J Budczies; S Wienert; F Klauschen
Journal:  Pathologe       Date:  2018-11       Impact factor: 1.011

3.  Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.

Authors:  Miseon Lee; In Ah Park; Sun-Hee Heo; Young-Ae Kim; Gyungyub Gong; Hee Jin Lee
Journal:  J Pathol Transl Med       Date:  2019-03-11

4.  Evaluating tumor-infiltrating lymphocytes in hepatocellular carcinoma using hematoxylin and eosin-stained tumor sections.

Authors:  Min Du; Yu-Meng Cai; Yu-Lei Yin; Li Xiao; Yuan Ji
Journal:  World J Clin Cases       Date:  2022-01-21       Impact factor: 1.337

Review 5.  Nanomaterial Technology and Triple Negative Breast Cancer.

Authors:  Kai Hou; Zeng Ning; Hongbo Chen; Yiping Wu
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.